Corporate Symposia

Corporate Symposia

Corporate Lunch Symposium 1: CarThera

Overcoming barriers: Ultrasound and the BBB

Friday, September 20, 13:05 - 14:20 hrs
Room: Bellecour

Chairs: Jean-Yves Delattre (Paris, FR), Roger Stupp (Chicago, US)

13:05 – 13:10Introduction
Jean-Yves Delattre (Paris, FR)
13:10 – 13:25

Efficiently tailoring local brain tumor therapy - challenges and surgical perspectives

Jörg Tonn (Munich, DE)
13:25 – 13:40Ultrasound based BBB Opening and results of phase 1 trial
Alexandre Carpentier (Paris, FR)
13:40 – 13:55Overcoming challenges in treating brain tumors
John De Groot (Houston, US)
13:55 – 14:10Summary review & perspectives
Roger Stupp (Chicago, US)
14:10- 14:20Q&A to speakers and Ahmed Idbaih (Paris, FR), principal investigator

Corporate Lunch Workshop 1: Illumina

DNA Methylation Profiling as a tool for Classifying Brain Tumors

Friday, September 20, 13:05 - 14:20 hrs
Room: Tête d'Or 1

13:05 – 13:15Welcome
Aida Soler (Madrid, ES) - Sr Segment Marketing Manager – Cancer Research, Illumina
13:15 – 14:05

DNA Methylation Profiling as a tool for Classifying Brain Tumors

Felix Sahm (Heidelberg, DE)
14:05 – 14:20Question and Answers


DNA methylation has proven to reliably identify tumor entities and even separate subgroups within entities that cannot be distinguished by histological evaluation. A joint effort of teams in Heidelberg and international collaborators has resulted in a machine learning-based algorithm that employs DNA methylation data to allot tumor specimen to the respective entity. Additionally, copy-number-variations are derived from the methylation data, informing about potentially relevant alterations. Application of this tool on ten-thousands of samples now also allows for identification of novel, so far unrecognized entities. The symposium will summarize the biological background of the approach, development and practical implementation of the classifier tool, and implications of ongoing research in this field.

Corporate Lunch Symposium 2: AbbVie Inc

Biomarkers and Therapies in GBM - What we have learned and what is new

Saturday, September 21, 12:45 - 14:00 hrs
Room: Bellecour

Chairs: Andreas von Deimling (Heidelberg, DE), Marc Sanson (Paris, FR), Martin van den Bent (Rotterdam, NL)


13:00 – 13:05Welcome and introduction
Marc Sanson (Paris, FR)
13:05 - 13:25Biomarkers in GBM
Andreas van Deimling (Heidelberg, DE)
13:25 - 13:45Therapies for GBM: Lessons learned and new developments
Martin van den Bent (Rotterdam, NL)
13:45 - 14:00Panel discussion

Corporate Symposium 3: Bristol-Myers Squibb

New Horizons for Immuno-Oncology and MGMT methylation in Glioblastoma

Saturday, September 21, 17:15 - 18:00 hrs
Room: Bellecour

Chairs: Michael Lim (Baltimore, US), Michael Weller (Zurich, CH)

17:15 – 17:25

Understanding of glioblastoma biology and MGMT promoter methylation as a biomarker – implications for management

Michael Weller

17:25 – 17:35

Immuno-oncology for treatment of GBM – current state

Michael Weller

17:35 – 17:45

Emerging findings in glioblastoma biology – strategies to overcome the immunosuppressive environment

Michael Lim

17:45 – 17:55

Immuno-oncology for treatment of GBM – Novel approaches


Michael Lim